Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...

Serial post-transplant chimerism assessment provided more reliable prognostic insight than a single early measurement.

A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...

Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...

Targeted maintenance therapy with gilteritinib (Xospata; Astellas) following allogeneic hematopoietic stem cell ...

Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...

Study from Japan shows near-tripling over 30-year period ...

Acute myeloid leukemia (AML) is one of the most aggressive and genetically complex cancers, marked by the unchecked growth of immature myeloid cells. Its diversity stems from numerous genetic ...

Leukemia is adept at dodging the immune system, making it resistant to many of the newest generation of cancer ...

Sellas Life Sciences Group Inc. (NASDAQ:SLS) is one of the best healthcare penny stocks to buy according to hedge funds. On ...